论文部分内容阅读
目的探讨不同剂量缬沙坦治疗慢性心功能不全的效果。方法选取2015年1月至2016年1月96例慢性心功能不全患者,随机分成Ⅰ组、Ⅱ组、Ⅲ组,每组32例。三组患者均采用常规方法治疗,Ⅱ组、Ⅲ组予以缬沙坦,应用剂量分别为80 mg/d、160 mg/d,观察治疗前与治疗4周、12周后的脑钠肽(BNP)、血管紧张素Ⅱ(AngⅡ)、血浆肾素(PRA)及左室舒张末期容积指数(LVEDVI)、左室射血分数(LVEF)变化。结果治疗4周、12周后,Ⅱ组、Ⅲ组LVEDVI低于Ⅰ组,Ⅲ组LVEF与Ⅰ组比较明显提高(P<0.05);Ⅱ、Ⅲ组间BNP、AngⅡ、PRA水平比较差异有统计学意义(P<0.05)。结论缬沙坦治疗慢性心功能不全效果显著,160 mg/d可明显逆转慢性心功能不全患者心室重构,改善心功能,不良反应少,临床应用价值更高。
Objective To investigate the effect of different doses of valsartan on chronic heart failure. Methods 96 patients with chronic cardiac insufficiency from January 2015 to January 2016 were randomly divided into group Ⅰ, group Ⅱ and group Ⅲ, with 32 in each group. Three groups of patients were treated by conventional methods. The patients in group Ⅱ and group Ⅲ were treated with valsartan at dosages of 80 mg / d and 160 mg / d respectively. The levels of BNP ), Ang Ⅱ, PRA, LVEDVI and LVEF were measured. Results After 4 and 12 weeks of treatment, the LVEDVI in group Ⅱ and group Ⅲ was lower than that in group Ⅰ. The LVEF in group Ⅲ was significantly higher than that of group Ⅰ (P <0.05), and the difference of BNP, AngⅡ and PRA between groups Ⅱ and Ⅲ was statistically significant Significance (P <0.05). Conclusions Valsartan is effective in treating chronic heart failure. 160 mg / d can obviously reverse the ventricular remodeling, improve cardiac function, fewer adverse reactions and higher clinical value in patients with chronic heart failure.